Clindamycin Phosphate

CHEMBL3184512 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
505.0 g/mol
LogP
-1.2
Phase
4

A phosphate ester prodrug of clindamycin used topically for acne and vaginosis, or intravenously for serious infections. After administration it is converted to active clindamycin, which inhibits bacterial protein synthesis.

Molekularmasse

505,0000 g/mol

LogP

-1,20

TPSA

174,00 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Wirkmechanismus

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCC[C@@H]1C[C@@H](C(=O)N[C@@H]([C@H]2O[C@H](SC)[C@H](OP(=O)(O)O)[C@@H](O)[C@H]2O)[C@H](C)Cl)N(C)C1

InChI

InChI=1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12+,13+,14-,15+,16+,18+/m0/s1

Molecular Formula

C18H34ClN2O8PS

HBD / HBA

5 / 10

Rotierbare Bindungen

9

Schwere Atome

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A phosphate ester prodrug of clindamycin used topically for acne and vaginosis, or intravenously for serious infections. After administration it is converted to active clindamycin, which inhibits bacterial protein synthesis.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Clindamycin Phosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3184512. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 443385. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.